Bioterror Patent Extensions Offered To Big Firms Under Revised Lieberman Bill
Executive Summary
Large biotech firms producing counterterrorism measures could receive a two-year extension of a patent for another product under legislation introduced by Sen. Joseph Lieberman (D-Conn.)
You may also be interested in...
BioShield House Compromise Could Serve As Template For Senate
The House Energy & Commerce Committee and White House funding compromise for Project BioShield could serve as a template for agreement in the Senate
BioShield House Compromise Could Serve As Template For Senate
The House Energy & Commerce Committee and White House funding compromise for Project BioShield could serve as a template for agreement in the Senate
PhRMA Urges Antitrust Exemption For Bioterrorism Research
An antitrust exemption to allow pharmaceutical companies to share production techniques for bioterrorism countermeasures will speed development of necessary agents, the Pharmaceutical Research & Manufacturers of America says